Full Text (PDF)
Review Article

Contribution of Dr. Paul Ehrlich: The Father of Immunology and Chemotherapy

Pethkar Shivani Anandrao, Kasumbiwal Ajay H., Lakhe Siddheshwar A., Munde Sudarshan

Author Information

Licence:

Attribution-Non-commercial 4.0 International (CC BY-NC 4.0)

This license enables reusers to distribute, remix, adapt, and build upon the material in any medium or format for noncommercial purposes only, and only so long as attribution is given to the creator.


Pediatric Education and Research 13(2 (Special Supplement -II)):p 508-511, July-Dec 2025. | DOI: https://doi.org/10.21088/per.2321.1644.13225.128

How Cite This Article:

Kasumbiwal Ajay H., Lakhe Siddheshwar A., Munde Sudarshan, et al. Contribution of Dr. Paul Ehrlich: The Father of Immunology and Chemotherapy. Pediatr. Edu. Res. 2025; 13(2): 508-511.

Timeline

Received : December 12, 2025         Accepted : December 19, 2025          Published : December 30, 2025

Abstract

Dr. Paul Ehrlich was a German physician and scientist whose groundbreaking contributions reshaped modern medicine. He is widely known as the “Father of Immunology” and the pioneer of chemotherapy, the use of chemical agents to treat disease. Ehrlich was selected for this paper because his discoveries not only laid the foundation for vaccines, antibody research, disease resistance, and drug development, but also saved millions of lives worldwide. He demonstrated that science driven by curiosity, persistence, and compassion has the power to transform the world of healthcare. Born in 1854 in Strehlen, Germany (now part of Poland), Ehrlich showed a deep interest in science from a young age. During his medical studies, he became fascinated with staining techniques and the way dyes could selectively bind to different cells and tissues. This curiosity led him to develop innovative laboratory methods that allowed scientists to better understand blood cells, bacteria, and the immune system. His work on staining techniques was not only important for research but also became a valuable diagnostic tool in pathology and microbiology. One of Ehrlich’s most significant contributions was his theory of immunity, known as the “side-chain theory.” Through this theory, he explained how antibodies are formed and how they protect the body against infections. This concept helped scientists understand how the immune system recognizes and fights foreign organisms, providing a scientific basis for vaccine development andimmunological research. His ideas strongly influenced future generations of researchers and remain relevant in modern immunology. Ehrlich’s work in chemotherapy was equally revolutionary. He believed in the idea of a “magic bullet,” a drug that could selectively target disease-causing organisms without harming healthy cells. After years of dedicated research, he developed Salvarsan (also known as Compound 606), the first effective treatment for syphilis. This discovery marked the beginning of modern antimicrobial therapy and opened the door to the development of many life-saving drugs. In recognition of his extraordinary contributions, Paul Ehrlich was awarded the Nobel Prize in Physiology or Medicine in 1908. His legacy continues to inspire scientists and healthcare professionals around the world. Through his relentless pursuit of knowledge and commitment to improving human health, Ehrlich proved that scientific innovation can profoundly change the course of medicine and enhance the quality of life for countless people. Key Message: Dr. Paul Ehrlich revolutionized medicine by proving that the human immune system can be understood, strengthened, and medically guided. Through his groundbreaking theories on immunity and his development of the first chemotherapy drug, he showed that scientific curiosity, persistence, and compassion can lead to discoveries that save millions of lives. His work teaches that innovation requires patience, courage to challenge existing beliefs, and a vision focused on improving humanity.


References

  • 1.   Silverstein A.M. Paul Ehrlich’s receptor immunology: The beginnings of modern immunology. Cell Immunol. 2002; 218(1–2): 1–9.
  • 2.   Kaufmann S.H. Immunology’s coming of age: Paul Ehrlich and the dawn of modern immunology. Nat Rev Immunol. 2008; 8(3): 185–194.
  • 3.   Bosch F., Rosich L. The contributions of Paul Ehrlich to pharmacology: A tribute on the occasion of the centenary of his Nobel Prize. Pharmacol Rev. 2008; 60(3): 307–314.
  • 4.   Tan S.Y., Grimes S. Paul Ehrlich (1854–1915): Father of chemotherapy. Singapore Med J. 2010; 51(11): 842–843.
  • 5.   Weatherall M. In search of a cure: A history of pharmaceutical discovery. Oxford: Oxford University Press; 1990. pp. 65–82.
  • 6.   Nobel Foundation. The Nobel Prize in Physiology or Medicine 1908: Paul Ehrlich – Biography. Stockholm: Nobel Media AB; 1908. pp. 1–6.
  • 7.   Strebhardt K., Ullrich A. Paul Ehrlich’s magic bullet concept: 100 years of progress. Nat Rev Cancer. 2008; 8(6): 473–480.
  • 8.   Greenwood B. Antimicrobial drugs: Chronicle of a twentieth century medical triumph. Med Hist. 1995; 39(3): 349–372.
  • 9.   Bendiner E. Great medical discoveries. New York: Wiley; 1982. pp. 133–148.
  • 10.   Parish H.J. A history of immunization. Edinburgh: Livingstone; 1965. pp. 201–215.

Data Sharing Statement

There are no additional data available. All raw data and code are available upon request.

Funding

This research received no funding.

Author Contributions

All authors contributed significantly to the work and approve its publication.

Ethics Declaration

This article does not involve any human or animal subjects, and therefore does not require ethics approval.

Acknowledgements

We would like to express our gratitude to the patients, their families, and all those who have contributed to this study.

Conflicts of Interest

No conflicts of interest in this work.


About this article


Cite this article

Kasumbiwal Ajay H., Lakhe Siddheshwar A., Munde Sudarshan, et al. Contribution of Dr. Paul Ehrlich: The Father of Immunology and Chemotherapy. Pediatr. Edu. Res. 2025; 13(2): 508-511.


Licence:

Attribution-Non-commercial 4.0 International (CC BY-NC 4.0)

This license enables reusers to distribute, remix, adapt, and build upon the material in any medium or format for noncommercial purposes only, and only so long as attribution is given to the creator.


Received Accepted Published
December 12, 2025 December 19, 2025 December 30, 2025

DOI: https://doi.org/10.21088/per.2321.1644.13225.128

Keywords

ChemotherapyImmunologyModern medicineAntibody resistanceDrug development

Article Level Metrics

Last Updated

Saturday 05 September 2026, 22:39:05 (IST)


1860

Accesses

11
192
00

Citations


NA
NA
NA

Download citation


Article Keywords


Keyword Highlighting

Highlight selected keywords in the article text.


Timeline


Received December 12, 2025
Accepted December 19, 2025
Published December 30, 2025

licence


Attribution-Non-commercial 4.0 International (CC BY-NC 4.0)

This license enables reusers to distribute, remix, adapt, and build upon the material in any medium or format for noncommercial purposes only, and only so long as attribution is given to the creator.


Access this article



Share